Evolving Role of Risk Tailored Therapy in Early Stage HER2-Positive Breast Cancer: A Canadian Perspective

The advent of HER2-targeted therapies has led to an important shift in the management of HER2-positive early breast cancer. However, initial treatment approaches apply uniform treatment regimens to all patients, with significant treatment-related and financial toxicities for both the patient and the...

Descripción completa

Detalles Bibliográficos
Autores principales: McGee, Sharon F., Clemons, Mark, Savard, Marie-France
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221562/
https://www.ncbi.nlm.nih.gov/pubmed/35735438
http://dx.doi.org/10.3390/curroncol29060329

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221562/
https://www.ncbi.nlm.nih.gov/pubmed/35735438
http://dx.doi.org/10.3390/curroncol29060329

Ejemplares similares